Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. CA2505661 - FORME POSOLOGIQUE A INNOCUITE PHARMACEUTIQUE

Office
Canada
Numéro de la demande 2505661
Date de la demande 18.12.2003
Numéro de publication 2505661
Date de publication 29.07.2004
Numéro de délivrance
Date de délivrance 14.06.2011
Type de publication C
CIB
A61K 9/00
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
9Préparations médicinales caractérisées par un aspect particulier
CPC
A61K 9/0004
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
0004Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
A61K 9/2081
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2072characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
2081with microcapsules or coated microparticles according to A61K9/50
A61K 9/209
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2072characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
209containing drug in at least two layers or in the core and in at least one outer layer
A61K 9/5073
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules ; having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
5073having two or more different coatings optionally including drug-containing subcoatings
A61K 9/5084
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules ; having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
Déposants MUTUAL PHARMACEUTICAL COMPANY, INC.
Inventeurs ROBERTS, RICHARD H.
Données relatives à la priorité 10339977 10.01.2003 US
Titre
(EN) PHARMACEUTICAL SAFETY DOSAGE FORMS
(FR) FORME POSOLOGIQUE A INNOCUITE PHARMACEUTIQUE
Abrégé
(EN)
Pharmaceutical safety dosage forms are provided which include a pharmaceutical and an antagonist to the pharmaceutical. The safety dosage forms are such that the antagonist has no significant bioavailability when the pharmaceutical safety dosage form is administered as intended. However, the antagonist is released and becomes bioavailable if the dosage form is disrupted. Methods of administering pharmaceuticals by providing pharmaceutical safety dosage forms are also provided.